Pacira Pharmaceuticals, Inc.

10578 Science Center Drive
Suite 125
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

SEC Filings

10-K
PACIRA PHARMACEUTICALS, INC. filed this Form 10-K on 03/01/2017
Entire Document
 << Previous Page | Next Page >>

Product Pipeline

DepoFoam is used to extend the release of active drug substances. With this technology, we are currently developing two new DepoFoam-based product candidates—DepoMLX, a non-steroidal anti-inflammatory drug, or NSAID, and DepoTXA, an antifibrinolytic. Completion of clinical trials may take several years or more. The length of time generally varies according to the type, complexity, novelty and intended use of a product candidate. We are also evaluating other potential DepoFoam products as pipeline candidates.

DepoTranexamic Acid

Tranexamic Acid, or TXA, is currently used off-label as a systemic injection or as a topical application, and is used to treat or prevent excessive blood loss during surgery by preventing the breakdown of a clot. However, the current formulation of TXA has a short-lived effect consisting of only a few hours, while the risk of bleeding continues for two to three days after surgery. We believe DepoTXA, a long-acting local antifibrinolytic agent combining immediate and extended release TXA, could address the unmet, increasing need for rapid ambulation and discharge in the ambulatory surgery environment for joint surgery (primarily orthopedic surgery, including spine and trauma procedures and cardiothoracic surgery). Designed for single-dose local administration into the surgical site, DepoTXA could provide enhanced hemostabilization and improved safety and tolerability for patients over the systemic use of TXA by reducing bleeding, the need for blood transfusions, swelling, soft tissue hematomas and the need for post-operative drains, thereby increasing vigor in patients while decreasing overall costs to the hospital system.

DepoTXA is currently in Phase 2 clinical development.

DepoMeloxicam

Our preclinical product candidate, DepoMLX, is a long-acting NSAID, designed to treat moderate to severe acute postsurgical pain as part of a non-opioid multimodal regimen. A product designed for single-dose local administration such as DepoMLX could provide a longer duration of pain relief at a significantly lower concentration of systemic NSAIDs, which are known to cause dose-dependent gastrointestinal side effects. Meloxicam, which is currently available as an oral formulation, is a commonly used NSAID on the market today. We expect our customer audience for this drug to be similar to the target for EXPAREL infiltration.
We expect to submit an Investigational New Drug application and subsequently initiate a Phase 1 clinical trial of DepoMLX in 2017.

Results of Operations
Comparison of Years Ended December 31, 2016, 2015 and 2014
Revenues
Our net product sales primarily include sales of EXPAREL in the United States and DepoCyt(e) in the United States and Europe. We also earn royalties based on sales by commercial partners of DepoCyt(e) and license fees and milestone payments from third parties.
The following table provides information regarding our revenues during the periods indicated, including percent changes (dollar amounts in thousands):
 
Year Ended December 31,
 
2016 versus
2015
 
2015 versus
2014
 
2016
 
2015
 
2014
 
% Increase / (Decrease)
Net product sales:
 
 
 
 
 
 
 
 
 
EXPAREL
$
265,802

 
$
239,851

 
$
188,528

 
11
 %
 
27
 %
DepoCyt(e) and other product sales
4,271

 
4,636

 
4,998

 
(8
)%
 
(7
)%
Total net product sales
270,073

 
244,487

 
193,526

 
10
 %
 
26
 %
Collaborative licensing and milestone revenue
3,426

 
1,426

 
1,287

 
140
 %
 
11
 %
Royalty revenue
2,872

 
3,084

 
2,855

 
(7
)%
 
8
 %
Total revenues
$
276,371

 
$
248,997

 
$
197,668

 
11
 %
 
26
 %

51

 << Previous Page | Next Page >>

Contact Investor Relations:
Susan Mesco
(973) 451-4030
Susan.Mesco@pacira.com


IHI/NPSF Project Seeks to Improve the Assessment and Management of Acute Pain
Click here for more...